Pulse Biosciences' Nanosecond Pulsed Field Ablation (nsPFA™) Technology to be Featured in Several Presentations at The Heart Rhythm 2023 Annual Meeting

Pulse Biosciences, Inc. , a company leveraging its novel and proprietary Nanosecond Pulsed Field Ablation technology for the treatment of atrial fibrillation, today announced nsPFA will be featured... | May 18, 2023

Related Keywords

United States ,Kevin Danahy ,Jacobs Koruth ,Nasdaq ,Pulse Biosciences Inc ,Pulse Biosciences ,Nanosecond Pulsed Field Ablation ,Heart Rhythm ,New Orleans ,Chief Executive Officer ,Deep Ventricular Lesions ,Imaging Insights ,Preclinical Evaluation ,Iwanari Kawamura ,Microscopic Insights ,Pulsed Field Ablation ,Halo Shaped Lesions ,Novel Multielectrode System ,Initial Preclinical Experience ,Nano Pulse Stimulation ,Nc Stock Exchange ,News ,Information ,Press Release ,Pulse ,Company ,Eleveraging ,Its ,Novel ,End ,Roprietary ,Nanosecond ,Repulsed ,Field ,Tablation ,Technology ,Or ,The ,Treatment ,F ,Trial ,Oday ,Nnounced ,Fspfa ,Hill ,E Plse Us74587b1017 ,